



## Curriculum Vitae

### Personal information

Edurne Lazaro

### Work experience

1. Employer: Agencia Española de Medicamentos y Productos Sanitarios
  - Start date: 2006
  - End date: 2011
  - Position: Pharmacovigilance staff
  - Activities: Coordination of the Spanish Pharmacovigilance System. Development and Maintenance of FEDRA 2. (Spanish ADR database).
  - Country: Spain
2. Employer: Agencia Española de Medicamentos y Productos Sanitarios
  - Start date: 2011
  - End date: 082021
  - Position: Head of Service Identification Risk Unit
  - Activities: Coordination of the Spanish Pharmacovigilance System. Responsible for FEDRA (Spanish ADR database) Member of EudraVigilance Expert Working Group Member of Pharmacovigilance Business Team
  - Country: Spain
3. Employer: Agencia Española de Medicamentos y Productos Sanitarios
  - Start date: 092021
  - End date: 082022
  - Position: Seconded National Expert at EMA
  - Activities: Data Analytics, Health Care Data at EMA.
  - Country: Spain
4. Employer: Agencia Española de Medicamentos y Productos Sanitarios
  - Start date: 092022
  - End date:
  - Position: Head of Service pharmaeepidemiology and pharmacovigilance.
  - Activities: Support to the Head of the Division,
  - Country: Spain

### Education and training

1. Subject: Universidad Complutense de Madrid
  - Start date: 1994
  - End date: 2000
  - Qualification: Bachelor in Pharmacy
  - Organisation:
  - Country: Spain
2. Subject: School of Medicine of the Universidad Complutense de Madrid
  - Start date: 2002
  - End date: 2003
  - Qualification: Master in Medicine
  - Organisation: Public Health Pharmacovigilance Antibiotic consumption.
  - Country: Spain
3. Subject: Universidad de Alcalá
  - Start date: 092014
  - End date: 062015
  - Qualification: Master in Pharmacoepidemiology and Pharmacovigilance
  - Organisation: Pharmacoepidemiology Pharmacovigilance
  - Country: Spain

### Additional information

#### Publications

- Thrombosis with Thrombocytopenia Syndrome following adenovirus vector-based vaccines to prevent COVID-19: epidemiology and clinical presentation in Spain. D. García Azorín, E. Lázaro, D. Ezpeleta, R. Lecumberrri, R. de la Cámara, M. Cartellanos, C. Iñiguez Martínez, L. Quiroga\_González, G. Elizondo Rivas, A. Sancho López, P. Rayo Iglesias, E. Segovia, C. Mejías, D. Montero Corominas. *Neurología* 2022 may 23. doi: 10.1016/j.nrl.2022.04.010. Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain—differences between regional pharmacovigilance centres and pharmaceutical industry. C. Fernández\_Fernández, E. Lázaro\_Bengoa, E. Fernández Antón, L. Quiroga\_González *Eur J Clin Pharmacol* 76, 1175\_1181 (2020). [https://doi.org/10.1007/s00228\\_020\\_02894\\_0](https://doi.org/10.1007/s00228_020_02894_0) Performance of probabilistic method to detect duplicate individual case safety reports. Tregunno PM, Fink DB, Fernandez\_Fernandez C, Lázaro\_Bengoa E, Norén GN. *Drug Saf.* 2014 Apr;37(4):249\_58. doi: 10.1007/s40264\_014\_0146\_y • Poster: 2013 (Montreal, Canadá): 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Tregunno, D Bech Fink, C Fernandez, E Lazaro, GN Norén. Hit\_miss model detects duplicates missed by rulebased. Poster [http://www.imi\\_protect.eu/documents/TregunnoPetalHit\\_missmodeldetectsduplicatesmissedbyrulebasedscreeningofindividualcasesafetyr.pdf](http://www.imi_protect.eu/documents/TregunnoPetalHit_missmodeldetectsduplicatesmissedbyrulebasedscreeningofindividualcasesafetyr.pdf)
- Significant ecological impact on the progression of fluoroquinolone resistance in *Escherichia coli* with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid. Cuevas O, Oteo J, Lázaro E, Aracil B, de Abajo F, García\_Cobos S, Ortega A, Campos J; Spanish EARS\_Net Study Group. *J Antimicrob Chemother.* 2011 Mar;66(3):664\_9. doi: 10.1093/jac/dkq471 • [Use of antibiotics in Spain and regulatory framework for clinical development in the European Union]. Lázaro\_Bengoa E, Iglesias FJ, López\_Navas A,

Fernández\_Cortizo MJ. *Enferm Infecc Microbiol Clin*. 2010 Nov;28 Suppl 4:10\_6. doi: 10.1016/S0213\_005X(10)70036\_7. Spanish. • Capitulo de libro: Los primeros 25 años del Sistema Español de Farmacovigilancia de medicamentos de Uso Humano. FEDRA: La base de datos del Sistema Español de Farmacovigilancia de Medicamentos de Uso Humano. M Madurga, E. Lázaro, G Martín\_Serrano, MC Quiroga. 131\_144: 2010: Ediciones de la Universidad de Oviedo, Oviedo. • Capitulo de libro: Los primeros 25 años del Sistema Español de Farmacovigilancia de medicamentos de Uso Humano. Sistema Español de Farmacovigilancia de Medicamentos de Uso Humano: su historia en cifras. M Madurga, E. Lázaro, G Martín\_Serrano, MC Quiroga. 31\_46: 2010: Ediciones de la Universidad de Oviedo, Oviedo. • Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended\_spectrum beta\_lactamase (ESBL)\_producing *Escherichia coli*. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, Lázaro E, de Abajo FJ, Campos J; Spanish ESBL\_EARS\_Net Study Group. *J Antimicrob Chemother*. 2010 Nov;65(11):2459\_63. doi: 10.1093/jac/dkq346 • Antibiotic resistance in *Haemophilus influenzae* decreased, except for beta\_lactamase\_negative amoxicillin\_resistant isolates, in parallel with community antibiotic consumption in Spain from 1997 to 2007 García\_Cobos S, Campos J, Cercenado E, Román F, Lázaro E, Pérez\_Vázquez M, de Abajo F, Oteo J. *Antimicrob Agents Chemother*. 2008 Aug;52(8):2760\_6. doi: 10.1128/AAC.01674\_07 • Increased amoxicillin\_clavulanic acid resistance in *Escherichia coli* blood isolates, Spain. Oteo J, Campos J, Lázaro E, Cuevas O, García\_Cobos S, Pérez\_Vázquez M, de Abajo FJ; Spanish Members of EARSS. *Emerg Infect Dis*. 2008 Aug;14(8):1259\_62. doi: 10.3201/eid1408.071059 • [Spanish pharmacovigilance system of vaccines]. Madurga M, Lázaro E, Montero D. *Med Clin (Barc)*. 2012 Feb 4;138(2):86. doi: 10.1016/j.medcli.2011.04.032. Epub 2011 Oct 19. Spanish. • Poster: "Medidas reguladoras sobre seguridad de medicamentos comunicadas durante 2008 por la AEMPS". IX Jornadas de Farmacovigilancia del SEFVH. Oviedo, Asturias. • Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data. Campos J, Ferech M, Lázaro E, de Abajo F, Oteo J, Stephens P, Goossens H. *J Antimicrob Chemother*. 2007 Sep;60(3):698\_701. • Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data. Campos J, Ferech M, Lázaro E, de Abajo F, Oteo J, Stephens P, Goossens H. *J Antimicrob Chemother*. 2007 Sep;60(3):698\_701. • Ampicillin\_resistant non\_beta\_lactamase\_producing *Haemophilus influenzae* in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. García\_Cobos S, Campos J, Lázaro E, Román F, Cercenado E, García\_Rey C, Pérez\_Vázquez M, Oteo J, de Abajo F. *Antimicrob Agents Chemother*. 2007 Jul;51(7):2564\_7.

#### Projects

Innovative Medicines Initiative \_Pharmacoepidemiological Research on Outcomes of Therapeutics (IMI\_PROTECT): Signal Detection: Duplicate detection in spontaneous report datasets.

#### Memberships

Member of the Pharmacovigilance Business Team. (Since he beginning\_current) SMART methodology (sept 2022\_current) Member of the EudraVigilance Expert Group. until sept 2021 Member of the Project and Maintenance Group 1 "Collection of key information on medicines" (2014\_the end of the group) Member in the Project 00305: Implementation of the new Pharmacovigilance legislation European Medicines Agency and Member States Joint Implementation, Project Team 1 "Collection of key information on medicines" (2011\_2014) Collaboration with E\_CDC (European Control Disease Center) and ESAC (European Surveillance Antibiotic Consumption). National expert in antibiotic consumption (2002\_2014)

#### Other Relevant Information